GlobeNewswire

2024-12-10 11:30

RenaissThera Closes Seed Funding to Drive AI-Powered Therapies for Cardio-Metabolic Diseases

BENGALURU, India, Dec. 10, 2024 (GLOBE NEWSWIRE) -- RenaissThera Private Limited (“RenaissThera”), a pioneering Bengaluru-based biotechnology company, has successfully closed its seed funding round backed by angel investors. This funding will accelerate the development of novel small-molecule therapies targeting GLP-1 and GIP receptors for Cardio-metabolic (CM) diseases, with an emphasis on diabetes and obesity. The company aims to address critical health challenges in underserved populations globally through affordable and transformative solutions.

RenaissThera is revolutionizing the fight against cardio-metabolic diseases like diabetes and obesity through its AI-powered Innovation Platform, leveraging Generative AI (GenAI) and machine learning to rapidly identify and optimize small molecules for targeted therapies. Mr. Sudhir Nagarajan, Managing Director, said, “We thank all the investors in this round for their support and belief in our team and the promise of RenaissThera in delivering innovative medicines.” With the successful close of its seed funding round, CEO Dr. Ramkesh Meena stated, “This milestone enables us to scale up and validate our early-stage pipeline in pre-clinical proof-of-concept studies and get ready for IND filing next year, propelling us closer to delivering life-changing, affordable therapies that address critical gaps in care.” This innovative approach combines scientific rigor and efficiency to reduce development timelines and costs while improving patient outcomes worldwide.

About RenaissThera

RenaissThera, based in Bengaluru, India, is a biotechnology company dedicated to developing affordable, novel small-molecule targeted therapies leveraging AI platforms. Our goal is to innovate for underserved populations and bridge the gaps in novel therapy access worldwide. We focus on high-unmet-need areas of prevalent diseases in key therapy areas such as Cardio-metabolic including diabetes and obesity indications. Leveraging our Innovation Platform powered by GenAI tools, we identify small-molecule therapies for proven pathways, ensuring cutting-edge solutions for patients.

For more information, visit www.renaissthera.com.


Contact Name: Lakshmi Ramakrishna
Email id: lramakrishna@renaissthera.com
Mob no. +91-9176940015

Primary Logo

source: RENAISSTHERA PRIVATE LIMITED

《說說心理話》成人亦會專注力不足?嘉賓分享中年確診過度活躍症+自閉症過程!► 即睇

上一篇新聞︰2024-12-10 12:00  XPENG G6 Achieves Five-Star ANCAP SAFETY Rating

下一篇新聞︰2024-12-10 07:00  BeyondBrain Unveils Lumi AI Travel Agent

人氣文章
最近7天
1
港股 | 蕭猷華:內地AI發展迅速,阿里巴巴股價看俏
2
PapaHome淘寶家具實體店22日開幕,選址尖沙咀中港城,料創100個就業機會
3
高息定存 | 華僑銀行推新春港元定存優惠,88天或188天享3.68厘
4
高息定存 | 一周高息合集,蛇年定存金蛇起舞,1個月定存高達8厘
5
英偉達 | DeepSeek衝擊AI晶片行業結構 英偉達暴跌仍未急抄底
6
啟德體育園明天足球賽測試,4.4萬公僕參與涉逾400萬車馬費
7
電騙 | 黃俊碩:多管齊下,防治內地留學生受騙
8
環球央行 | 歐洲央行宣布再次減息0.25厘,符合市場預期
9
高息定存 | 一周高息合集,3個月5厘之選有邊間?6個月最高3.55厘
10
高息定存 | 一周高息合集,減息預期降溫,銀行3個月最高5.68厘,6個月3.55厘
11
專訪 | 關稅戰 | 香港物流協會副會長梁庭彰:美物流商停收包裹對跨境電商打擊重大
12
易經看世界 | 乙巳蛇年趨吉五招:言行注意甚麼?應遠離甚麼人?(有片)
13
港股 | 午市前瞻 | iPhone SE難救中國市場 專家提醒比電已超買
14
【FOCUS】螺絲殼裏做道場,DeepSeek致勝啟示
15
【FOCUS】悟空、哪吒、DeepSeek,如何啟示香港
16
DeepSeek推出即上蘋果中國區榜首,能力直追OpenAI
17
大S | 台灣藝人徐熙媛因流感併發肺炎逝世,享年48歲
18
收市短打 | 楊韻銳:港股升勢有成交配合 惟留意關鍵阻力位!
19
日入而息 | 習近平據報下周見科企領袖,證監會審視8券商孖展風控,大酒店轉蝕9億
20
高息定存 | 信銀國際12個月港元定存高達3.5厘
21
彭博亞洲20大富裕家族,香港5大家族上榜,新地郭氏排名最高,無李嘉誠李兆基?
22
港股 | 午市前瞻 | AI應用概念炒作有錢途 下階段部署邊隻好?
23
民營企業座談會 | 習近平在京出席民營企業座談會
24
David Webb:因病情惡化,將有序結束個人財經網站
25
AI | 蔡崇信確認阿里與蘋果合作,撰文談DeepSeek崛起帶來兩大啟示
26
神州經脈 | 習近平:經濟政策不會變,民企大顯身手正當其時
27
港股 | 蕭猷華:恒指升勢可持續?
28
譚仔 | 譚仔國際日資大股東溢價76%建議私有化今復牌,上市不足三年半
29
AI | 追捧DeepSeek,全球對沖基金棄印度投中國
30
美股收盤 | 美股三大指數收市報跌,道指跌近750點
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

etnet榮膺「第九屆傳媒轉型大獎」四大獎項

【限時優惠$68/月】申請etnet強化版MQ手機串流報價服務 捕捉板塊輪動,提高獲利勝算

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

大國博弈

2025-26年度財政預算案

貨幣攻略

說說心理話

Watch Trends 2024

北上食買玩

Art Month 2024

理財秘笈

流感高峰期

山今養生智慧

輕鬆護老